ArticleThe Journal of pediatrics2013
Safety and efficacy of cyproheptadine for treating dyspeptic symptoms in children.
Article in The Journal of pediatrics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- ESPGHAN/NASPGHAN guidelines for treatment of irritable bowel syndrome and functional abdominal pain-not otherwise specified in children aged 4-18 years.Journal of pediatric gastroenterology and nutrition · 2025Guideline
- Cardiac Vagal Efficiency Is Enhanced by Percutaneous Auricular Neurostimulation in Adolescents With Nausea: Moderation by Antidepressant Drug Exposure.Neurogastroenterology and motility · 2025Trial
- Rome V Pediatric Upper Gastrointestinal Disorders of Gut-Brain Interaction.Gastroenterology · 2026Review
- Ten-Year Trends in Pharmacologic Management of Gastroesophageal Reflux Disease and Pediatric Feeding Disorders in Young Children.The Journal of pediatrics · 2025Article
- Liquid and solid gastric emptying and correlation with clinical characteristics in pediatric patients with dyspepsia.Neurogastroenterology and motility · 2024Article
- Gut dysmotility in children with neurological impairment: the nutritional management.Frontiers in neurology · 2023Review
- Percutaneous electrical nerve field stimulation compared to standard medical therapy in adolescents with functional abdominal pain disorders.Frontiers in pain research (Lausanne, Switzerland) · 2023Article
- A comprehensive review of functional dyspepsia in pediatrics.Clinical journal of gastroenterology · 2022Review
- Functional Nausea Is Real and Makes You Sick.Frontiers in pediatrics · 2022Review
- An Update on the Assessment and Management of Pediatric Abdominal Pain.Pediatric health, medicine and therapeutics · 2021Review
- Article
- Safety of Cyproheptadine, an Orexigenic Drug. Analysis of the French National Pharmacovigilance Data-Base and Systematic Review.Frontiers in pediatrics · 2021Article
- The Effects of the Rome IV Criteria on Pediatric Gastrointestinal Practice.Current gastroenterology reports · 2020Review
- Gastric electrical stimulation: An emerging therapy for children with intractable gastroparesis.World journal of gastroenterology · 2019Review
- How does one choose the appropriate pharmacotherapy for pediatric patients with functional dyspepsia?Expert opinion on pharmacotherapy · 2019Article
- Article
- The Management of Paediatric Functional Abdominal Pain Disorders: Latest Evidence.Paediatric drugs · 2018Review
- Feeding Intolerance in Children with Severe Impairment of the Central Nervous System: Strategies for Treatment and Prevention.Children (Basel, Switzerland) · 2017Review
- Functional Nausea in Children: A Review of the Literature and Need for Diagnostic Criteria.Children (Basel, Switzerland) · 2016Review
- Visceral hypersensitivity and electromechanical dysfunction as therapeutic targets in pediatric functional dyspepsia.World journal of gastrointestinal pharmacology and therapeutics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo present our experience using cyproheptadine, a potent serotonin antagonist used to stimulate appetite, to treat dyspeptic symptoms in children. STUDY
designThis was a retrospective open-label study conducted to evaluate the safety and efficacy of cyproheptadine in children with refractory upper gastrointestinal symptoms (eg, nausea, early satiety, vomiting, retching after fundoplication, abdominal pain). Response was graded as resolution if symptoms resolved and medication was discontinued, as significant improvement if symptoms resolved with no further interventions, and as failure with any other outcome.
resultsA total of 80 children (65% females) aged <12 years (mean age, 10 years) were included. Response to therapy was reported in 55% of patients. Multivariate analysis revealed better response in children and females (P = .04 and .03, respectively). No associations were found between response to therapy response and gastric emptying, antroduodenal manometry, functional dyspepsia, vomiting, and use of cyproheptadine as first therapy. Early vomiting (occurring within 1 hour after starting a meal) responded better than late vomiting (P = .03), and patients with retching after undergoing Nissen fundoplication had an 86% response rate. Twenty-four patients (30%) complained of side effects, all mild, including somnolence (16%), irritability and behavioral changes (6%), increased appetite and weight gain (5%), and abdominal pain (2.5%), but only 2 of these patients discontinued therapy. Multivariate analysis demonstrated an association between side effects and lack of response to therapy (P = .04), but no associations with age and sex.
conclusionCyproheptadine is safe and effective for treating dyspeptic symptoms in children, particularly in young children and those with early vomiting and retching after fundoplication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.